Document Detail


Inverse correlation between the changes of lumbar bone mineral density and serum undercarboxylated osteocalcin after vitamin K2 (menatetrenone) treatment in children treated with glucocorticoid and alfacalcidol.
MedLine Citation:
PMID:  11403096     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
We have reported that alfacalcidol plus menatetrenone, a vitamin K2 with four isoprene units (menaquinone-4), treatment is useful for improving bone problems in children with skeletal unloading. The aim of this study was to evaluate the effect of menatetrenone on bone metabolism in long-term glucocorticoid-treated children with alfacalcidol treatment. Twenty children who had been treated with fixed dosages of prednisolone and alfacalcidol (0.03 microg/kg/day) for 24 weeks were enrolled in a prospective pilot study, and assigned to receive alfacalcidol (0.03 microg/kg/day) or alfacalcidol (0.03 microg/kg/day) plus menatetrenone (approximately 2 mg/kg/day). Bone biochemical markers and bone mineral density (BMD) were measured at baseline and after the 12-week treatment. In the group receiving alfacalcidol plus menatetrenone, serum carboxylated osteocalcin (OC) (p =0.0022) and lumbar BMD (p=0.0029) increased and serum undercarboxylated OC (p=0.0004) decreased significantly in comparison to the group receiving alfacalcidol; further, the change of lumbar BMD showed an inverse correlation to the change of serum undercarboxylated OC (r=-0.744, p=0.0134) and positive correlations to the baseline values of bone turnover markers such as serum levels of intact OC, bone-specific alkaline phosphatase and type I procollagen carboxyl extension peptide and urinary levels of deoxypyridinoline and N-telopeptide of type I collagen. No adverse effect was observed. This is a small short-term study, but its results suggest that menatetrenone effectively and safely increases lumbar BMD probably through carboxylation of OC in long-term prednisolone-treated children with alfacalcidol treatment who have a high bone turnover. Randomized double-blind controlled trials are needed to confirm our findings.
Authors:
T Inoue; T Sugiyama; T Matsubara; S Kawai; S Furukawa
Related Documents :
7651756 - Progressive normalization of growth hormone-binding protein and igf-i levels in treated...
21774746 - Minimal residual disease in cerebrospinal fluid at diagnosis: a more intensive treatmen...
18793346 - Common exon 3 polymorphism of the gh receptor (ghr) gene and effect of gh therapy on gr...
8580216 - Bone mineral status in preterm-born children: assessment by dual-energy x-ray absorptio...
19833976 - A suggested approach to the etiologic evaluation of status epilepticus in children: wha...
7651756 - Progressive normalization of growth hormone-binding protein and igf-i levels in treated...
Publication Detail:
Type:  Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Endocrine journal     Volume:  48     ISSN:  0918-8959     ISO Abbreviation:  Endocr. J.     Publication Date:  2001 Feb 
Date Detail:
Created Date:  2001-06-13     Completed Date:  2001-10-25     Revised Date:  2013-05-27    
Medline Journal Info:
Nlm Unique ID:  9313485     Medline TA:  Endocr J     Country:  Japan    
Other Details:
Languages:  eng     Pagination:  11-8     Citation Subset:  IM    
Affiliation:
Department of Pediatrics, Yamaguchi University School of Medicine, Ube, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adolescent
Bone Density* / drug effects
Child
Child, Preschool
Female
Glucocorticoids / adverse effects*,  therapeutic use
Humans
Hydroxycholecalciferols / therapeutic use*
Lumbar Vertebrae*
Male
Osteocalcin / blood*,  chemistry
Osteoporosis / chemically induced
Prednisolone / adverse effects,  therapeutic use
Prospective Studies
Vitamin K / analogs & derivatives,  blood,  therapeutic use*
Vitamin K 2 / analogs & derivatives
Chemical
Reg. No./Substance:
0/Glucocorticoids; 0/Hydroxycholecalciferols; 104982-03-8/Osteocalcin; 11032-49-8/Vitamin K 2; 12001-79-5/Vitamin K; 27Y876D139/menatetrenone; 50-24-8/Prednisolone; URQ2517572/alfacalcidol

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  A case of aldosterone-producing adrenocortical adenoma associated with preclinical Cushing's syndrom...
Next Document:  Severe hypercholesterolemia in a double heterozygote for lipoprotein lipase deficiency (LPL(Arita)) ...